Related Experiment Video
Updated: Nov 28, 2025
07:50
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
5.9K
Genetic profiling for diffuse type and genomically stable subtypes in gastric cancer.
Yiwei Ling1, Yu Watanabe1, Mayuki Nagahashi2
1Division of Bioinformatics, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan.
Computational and Structural Biotechnology Journal
|November 26, 2020
Summary
This study compares genetic profiles of diffuse and genomically stable (GS) gastric cancer subtypes. Distinct genetic characteristics were identified, aiding precision medicine for gastric cancer treatment.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Gastric cancer is a major global health concern.
- Traditional Lauren classification divides gastric cancer into diffuse and intestinal subtypes.
- New molecular classifications are emerging from cancer genomics research.
Purpose of the Study:
- To perform genetic profiling of recurrently mutated genes in diffuse and genomically stable (GS) gastric cancer subtypes.
- To identify molecular functions and mutational signatures characteristic of each subtype.
- To advance the clinical application of diffuse and GS subtypes in precision medicine.
Main Methods:
- Genetic profiling of recurrently and significantly mutated genes.
- Comparative analysis of diffuse and GS gastric cancer tumors.
- Identification of molecular functions and mutational signatures.
Main Results:
- Significantly different genetic characteristics were observed between diffuse and GS subtypes.
- Overlap exists between the histopathologically diffuse type and the genomically stable (GS) subtype.
- Distinct molecular functions and mutational signatures were identified for each subtype.
Conclusions:
- The genetic profiles of diffuse and GS gastric cancer subtypes are distinct.
- Understanding these genetic differences is crucial for precision medicine.
- This research supports tailored treatment strategies for gastric cancer patients.
